TriangleHEALTH PROFESSIONAL · SOURCE READING
Noncovalent BTK inhibitors
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Unlike other BTK inhibitors (ibrutinib, acalabrutinib, and zanubrutinib), pirtobrutinib binds to BTK in a noncovalent manner.[6]
Source links and citations
In a prospective phase I/II study, 317 patients with CLL/small lymphocytic leukemia received pirtobrutinib. A total of 247 of these patients had been treated previously with a covalent-binding BTK inhibitor.[7]
Source links and citations
In a prospective phase I/II study, 317 patients with CLL/small lymphocytic leukemia received pirtobrutinib. A total of 247 of these patients had been treated previously with a covalent-binding BTK inhibitor.[7]
With a median follow-up of 19.4 months, the median progression-free survival (PFS) was 19.6 months (95% confidence interval [CI], 16.9–22.1) for all patients and 16.8 months (95% CI, 13.2–18.7) for the subgroup of patients with BTK inhibitor resistance, intolerance, or BTK C481 variants (a resistance variant for the covalent agents).[7][Level of evidence C3]
Source links and citations
In a prospective phase I/II study, 317 patients with CLL/small lymphocytic leukemia received pirtobrutinib. A total of 247 of these patients had been treated previously with a covalent-binding BTK inhibitor.[7]
In this trial, 82 patients had a diagnosis of Richter transformation. Among those patients, the overall response rate was 50.0% (95% CI, 38.7%–61.3%), and the complete response rate was 13%.[8][Level of evidence C3]
Source links and citations
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice